[This Week's IPO] November Third Week Demand Forecast and Subscription Schedule

This month (November), in the third week, Dukem Bio and Oreum Therapeutics will conduct demand forecasting for institutional investors.

◆Dukem Bio= Dukem Bio holds over 90% market share in the domestic Alzheimer's dementia diagnostic market. The upcoming domestic launch of the global dementia drug Leqembi (developer Eisai, Biogen) also raises expectations for future performance.

A total of 1.43 million shares will be offered. The desired offering price is KRW 12,300 to KRW 14,100 per share. Demand forecasting for institutional investors will be conducted from the 20th to the 26th of this month to finalize the offering price, followed by a general subscription from December 2nd to 3rd. The listing underwriter is NH Investment & Securities.

◆Oreum Therapeutics= Oreum Therapeutics is a leading bio company in the antibody-drug conjugate (ADC) field based on the dual precision targeted protein degradation approach ‘TPD²®’. ADC is gaining attention as a next-generation modality that selectively delivers targeted protein degraders (TPD,) to target cells via antibodies and degrades target proteins within cells.

A total of 3 million shares will be offered. The desired offering price is KRW 30,000 to KRW 36,000. Demand forecasting for institutional investors will be conducted from the 21st to the 27th, followed by a general subscription on December 3rd to 4th. The underwriter is Korea Investment & Securities.